PHXM Stock - PHAXIAM Therapeutics S.A.
Unlock GoAI Insights for PHXM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $5.28M |
| Gross Profit | $-1,608,000 | $-2,908,000 | $-5,377,000 | $-4,991,000 | $1.07M |
| Gross Margin | N/A | N/A | N/A | N/A | 20.2% |
| Operating Income | $-25,417,000 | $-32,083,000 | $-56,515,000 | $-72,550,000 | $5.28M |
| Net Income | $-23,488,000 | $-227,000 | $-53,797,000 | $-73,300,000 | $-62,659,000 |
| Net Margin | N/A | N/A | N/A | N/A | -1186.0% |
| EPS | $-4.62 | $-0.10 | $-22.70 | $-36.55 | $-3.49 |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Visit WebsiteEarnings History & Surprises
PHXMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2024 | Mar 26, 2024 | — | — | — | — |
Q3 2023 | Sep 21, 2023 | — | — | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.19 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.17 | — | — |
Q2 2022 | Jun 30, 2022 | — | $0.35 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.38 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.39 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.49 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.61 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.55 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.98 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.98 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.97 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.98 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-1.08 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.78 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.98 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-6.50 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.48 | — | — |
Q3 2018 | Sep 30, 2018 | — | $-0.60 | — | — |
Latest News
Frequently Asked Questions about PHXM
What is PHXM's current stock price?
What is the analyst price target for PHXM?
What sector is PHAXIAM Therapeutics S.A. in?
What is PHXM's market cap?
Does PHXM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PHXM for comparison